EORTC Quality of Life Questionnaire QLQ-C30

Abstract

The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is one of the most widely utilized, rigorously validated, and internationally accepted patient-reported outcome measures (PROMs) in clinical oncology. Developed by the EORTC Quality of Life Group, the instrument assesses health-related quality of life (HRQoL) in cancer patients participating in international clinical trials, comparative effectiveness research, and routine clinical practice. The QLQ-C30 consists of 30 items organized into a modular psychometric architecture comprising five multi-item functional scales (physical, role, emotional, cognitive, and social functioning), three multi-item symptom scales (fatigue, pain, and nausea/vomiting), a two-item global health status/quality of life scale, and six single-item symptom and financial impact scales (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).

Items 1 through 28 employ a 4-point Likert-type response scale ranging from 1 ("Not at All") to 4 ("Very Much") referencing a 1-week recall period, while items 29 and 30 utilize a 7-point modified linear analog scale ranging from 1 ("Very poor") to 7 ("Excellent"). In accordance with the standard EORTC scoring algorithm, raw scores are linearly transformed into standardized metrics ranging from 0 to 100. Higher scores on functional scales reflect superior, healthier functional capacity; higher scores on the global health status scale denote superior overall quality of life; conversely, higher scores on symptom scales and single items reflect greater symptom burden, impairment, and morbidity.

Extensive psychometric investigations across diverse international oncological cohorts confirm that the QLQ-C30 demonstrates robust internal consistency reliability (with Cronbach’s alpha coefficients typically exceeding 0.70 for most scales, ranging from 0.52 to 0.90 across international cohorts), well-documented test-retest stability (intraclass correlation coefficients generally ≥ 0.80), robust convergent and discriminant validity, known-groups discriminative validity linked to clinical markers such as the Karnofsky Performance Scale and ECOG performance status, and high responsiveness to longitudinal clinical changes. Currently translated and cross-culturally validated in more than 100 languages, the QLQ-C30 serves as the foundational core of the EORTC modular measurement system.

Keywords

EORTC QLQ-C30, Health-Related Quality of Life, oncology, patient-reported outcome measures, psychometrics, cancer clinical trials, functional assessment, symptom burden, linear transformation, construct validity

Authors

The EORTC Quality of Life Questionnaire was conceptualized, operationalized, and continuously refined by the international multidisciplinary members of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group. Key foundational investigators include:

• Neil K. Aaronson, Ph.D. — Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
• Marianne A. G. Sprangers, Ph.D. — Department of Medical Psychology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
• Sam H. Ahmedzai, M.D. — Department of Palliative Medicine, University of Sheffield Medical School, Sheffield, United Kingdom.
• Monika Bullinger, Ph.D. — Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
• David Osoba, M.D. — Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
• Peter M. Fayers, Ph.D. — Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, Scotland, United Kingdom, and Quality of Life Group Methodologist.
• Stein Kaasa, M.D., Ph.D. — Department of Oncology and Palliative Medicine, Oslo University Hospital, University of Oslo, Norway.
• Anne Cull, Ph.D. — Imperial Cancer Research Fund, Psychology Research Group, Western General Hospital, Edinburgh, Scotland, United Kingdom.

Correspondence regarding instrument administration, licensing, and translations is officially coordinated via the EORTC Quality of Life Department, Avenue E. Mounier 83/11, 1200 Brussels, Belgium (Website: https://qol.eortc.org/).

Purpose

Historically, the empirical evaluation of cancer therapeutic interventions relied almost exclusively on biomedical and physiological primary endpoints, including overall survival (OS), progression-free survival (PFS), tumor objective response rates (ORR), and laboratory-quantified toxicities documented via clinician-rated scales such as the Common Terminology Criteria for Adverse Events (CTCAE). However, these physician-centric parameters frequently fail to capture the profound, subjective physical, psychological, and social sequelae experienced by cancer patients undergoing systemic chemotherapy, radiation therapy, immunotherapy, or extensive surgical resections.

The primary clinical and psychometric purpose of the EORTC QLQ-C30 is to provide a standardized, psychometrically sound, self-administered system capable of quantifying the multidimensional construct of health-related quality of life directly from the patient’s subjective perspective. It was specifically engineered to be brief and easily completed by acutely or chronically ill cancer patients without imposing excessive administrative burden, while remaining conceptually comprehensive enough to evaluate key functional domains and common cancer-related symptoms.

In modern oncology, the QLQ-C30 serves several distinct research and clinical functions:

• Primary and Secondary Clinical Trial Endpoints: Regulatory agencies, including the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), formally recognize that therapeutic interventions demonstrating equivalent survival must be evaluated based on symptom alleviation and preserved functional status. The QLQ-C30 serves as a validated PROM endpoint to support drug labeling claims and health technology assessments.
• Comparative Effectiveness Research: The instrument facilitates direct comparison between distinct treatment modalities (e.g., radical prostatectomy vs. external beam radiotherapy; aggressive multi-agent chemotherapy vs. maintenance targeted therapies) regarding their trajectory of functional compromise and recovery.
• Longitudinal Toxicity Monitoring and Symptom Detection: In routine clinical practice, longitudinal completion of the QLQ-C30 enables early identification of insidious symptoms (such as profound cancer-related fatigue, unaddressed emotional distress, or progressive cognitive dysfunction) that are routinely underestimated or underreported during standard clinical consultations.
• Prognostic Stratification: Extensive contemporary epidemiological literature indicates that baseline HRQoL scores assessed by the QLQ-C30 (particularly physical functioning, appetite loss, and global quality of life) possess independent prognostic value for overall survival, frequently rivaling or exceeding classical physiological prognostic factors.

Psychological Construct

The EORTC QLQ-C30 operationalizes Health-Related Quality of Life as a multi-tiered, latent construct encompassing multidimensional functioning, symptom-induced distress, and overall cognitive evaluation of personal well-being. The instrument divides this global construct into fifteen distinct subscales and single items across three overarching domains:

1. Functional Scales

The functional domain captures the patient’s perceived capacity to execute essential biological, behavioral, psychological, and social operations. This domain incorporates five distinct subscales:

• Physical Functioning (Items 1–5): Assesses basic and instrumental mobility, physiological vigor, and basic activities of daily living (ADLs). It covers high-energy exertion (e.g., carrying heavy shopping bags or suitcases), intermediate mobility (taking long walks), basic ambulation (taking short walks outside), severe physical confinement (needing to remain in bed or a chair), and biological self-care dependencies (eating, dressing, bathing, or using the toilet).
• Role Functioning (Items 6–7): Evaluates the degree to which physical morbidity or treatment-related toxicities constrain the individual’s occupational capacity, domestic management, work performance, and engagement in leisure pursuits or personal hobbies.
• Emotional Functioning (Items 21–24): Quantifies affective and psychological distress across four core internalizing manifestations: somatic tension (feeling tense), generalized anxiety and apprehension (worrying), affective reactivity and dysregulation (feeling irritable), and dysphoric mood states (feeling depressed).
• Cognitive Functioning (Items 20, 25): Measures subjective cognitive impairment (frequently termed "chemobrain" or cancer-related cognitive decline), specifically probing attentional control and executive processing (difficulty concentrating while reading a newspaper or watching television) alongside short-term memory retrieval (difficulty remembering things).
• Social Functioning (Items 26, 27): Assesses systemic psychosocial disruption, specifically the extent to which medical pathology and therapeutic protocols interfere with immediate family life, marital dynamics, and broader social/recreational networks.

2. Symptom Scales and Single Items

The symptom domain captures the sensory, somatic, and systemic burdens directly attributable to malignant disease processes or the toxic side effects of antineoplastic therapies:

• Fatigue (Items 10, 12, 18): A three-item scale evaluating the hallmark constellation of cancer-related fatigue, comprising subjective exhaustion, chronic physical weakness, and the overwhelming daily biological requirement for rest.
• Nausea and Vomiting (Items 14, 15): A two-item scale quantifying gastrointestinal distress, emetic reflexes, and subjective queasiness, particularly relevant for cytotoxic therapies.
• Pain (Items 9, 19): Probes both the subjective sensory presence of pain and the degree to which pain causes behavioral interference with routine activities.
• Single Symptom Items: Evaluating common, distinct clinical sequelae through isolated items: Dyspnea (Item 8), reflecting subjective shortness of breath; Insomnia (Item 11), assessing sleep latency, fragmentation, or disruption; Appetite Loss (Item 13), tracking anorexia and diminished oral intake; Constipation (Item 16) and Diarrhea (Item 17), tracking bowel motility disturbances; and Financial Difficulties (Item 28), capturing the socioeconomic toxicity and monetary strain secondary to oncological care.

3. Global Health Status / Quality of Life Scale

Items 29 and 30 require the respondent to integrate their physical sensations, psychological morale, functional limitations, and environmental adjustments into an overarching evaluative judgment of their overall physical health and subjective quality of life during the preceding 7 days. This two-item scale provides a holistic summary metric that transcends specific symptomatology.

Theoretical Framework

The conceptual foundation of the EORTC QLQ-C30 is anchored in two primary theoretical orientations: the biopsychosocial model of medicine (Engel, 1977) and Wilson and Cleary’s (1995) seminal Conceptual Model of Patient Outcomes.

The Biopsychosocial and Modular Paradigm

Historically, biomedical paradigms viewed disease eradication as the sole metric of therapeutic success. In contrast, the biopsychosocial model asserts that illness manifestations, functional adaptations, and subjective recovery are shaped by the dynamic interplay among biological factors (cellular pathology, chemotherapy-induced cytopenias), psychological processes (coping, cognitive appraisal, affective equilibrium), and social parameters (role expectations, interpersonal support systems). The EORTC Quality of Life Group operationalized this conceptualization by creating an overarching modular system (Sprangers et al., 1993). In this modular architecture, the QLQ-C30 serves as the "core" instrument, assessing universal dimensions of health, functioning, and symptoms shared across virtually all cancer populations regardless of anatomical site. When nuanced clinical granularity is required, disease-specific modules (e.g., QLQ-BR23 for breast cancer, QLQ-LC13 for lung cancer, QLQ-PR25 for prostate cancer) are appended to assess local symptoms and unique treatment sequelae.

Wilson and Cleary’s Hierarchy of Patient Outcomes

The theoretical taxonomy formulated by Wilson and Cleary (1995) provides an ideal lens for understanding the structural levels of the QLQ-C30:

1. Biological and Physiological Variables: Cellular malignant processes, metabolic abnormalities, and therapeutic tissue destruction.
2. Symptom Status: The patient’s perception of biological disruptions, operationalized in the QLQ-C30 as fatigue, pain, dyspnea, nausea, and gastrointestinal disturbances.
3. Functional Status: The patient’s capacity to execute physical actions, occupational duties, cognitive tasks, and social roles (captured via the five functional scales).
4. General Health Perceptions: The cognitive synthesis of biological, symptomatic, and functional states into an integrated perception of overall health (captured by Item 29).
5. Overall Quality of Life: The highest-order psychological appraisal representing subjective well-being, life satisfaction, and meaning, evaluated directly via Item 30.

Within this theoretical model, the QLQ-C30 captures the psychological reality that two patients with identical biological disease burdens (e.g., stage IV non-small cell lung carcinoma) may report dramatically divergent functional and overall quality of life outcomes based on psychological resilience, cognitive appraisal, palliative interventions, and socioeconomic cushions.

Validity

The psychometric validity of the EORTC QLQ-C30 has been scrutinized across hundreds of international peer-reviewed validation studies, phase III randomized controlled trials, and observational registries across diverse oncology patient cohorts.

Construct and Known-Groups Validity

In the foundational international field validation conducted across 13 countries in North America and Western Europe (Aaronson et al., 1993; N = 305 lung cancer patients), the QLQ-C30 demonstrated substantial known-groups construct validity. Statistically significant score differentials (p < .001 to p < .05) were documented between patient cohorts stratified by baseline clinical parameters: patients with advanced disease vs. localized disease, and patients with poor performance status (ECOG performance status 2–4 or Karnofsky score ≤ 70) vs. good performance status (ECOG 0–1 or Karnofsky ≥ 80). Specifically, physical functioning, role functioning, fatigue, and global quality of life scores consistently separated distinct performance strata by clinically meaningful magnitudes.

Convergent and Discriminant Validity

Multitrait scaling analysis has repeatedly corroborated the convergent and discriminant validity of the hypothesized scale structure. Item-scale correlations demonstrate that individual items correlate substantially more strongly with their hypothesized scale (typically r ≥ .50, corrected for item overlap) than with competing dimensions, confirming item convergent and discriminant validity. Furthermore, when compared against alternative validated self-report instruments:

• The QLQ-C30 Physical Functioning scale correlates strongly (r > .70) with the Physical Component Summary (PCS) of the Medical Outcomes Study 36-Item Short Form Survey (SF-36) and the Functional Assessment of Cancer Therapy-General (FACT-G) physical well-being domain.
• The Emotional Functioning scale correlates strongly with the Hospital Anxiety and Depression Scale (HADS) anxiety and depression subscales (r values typically ranging from −.60 to −.78, where negative signs reflect opposing scoring directions).
• The Fatigue and Pain subscales correlate highly with the Brief Fatigue Inventory (BFI) and Brief Pain Inventory (BPI), respectively, supporting robust convergent validity.

Responsiveness to Longitudinal Change

A critical psychometric attribute for any clinical trial instrument is its sensitivity to detect clinically meaningful changes over time. Multiple prospective investigations (e.g., Osoba et al., 1998) have demonstrated that when patients report subjective clinical improvement or deterioration, the corresponding QLQ-C30 domain scores shift accordingly. Based on anchor-based and distribution-based methodologies, empirical consensus defines a 5 to 10-point mean shift on the 0–100 scale as a "small" but clinically perceptible minimally important difference (MID), a 10 to 20-point change as a "moderate" clinical shift, and shifts greater than 20 points as large, profound alterations in health status.

Reliability

The reliability of the EORTC QLQ-C30 has been established in both cross-sectional and longitudinal empirical investigations across heterogeneous oncological diagnoses.

Internal Consistency Reliability

Across the historical evolution from version 1.0 to version 3.0, the internal consistency of the multi-item subscales has consistently met or exceeded the recognized standard for group-level clinical research (Cronbach’s α ≥ .70):

• Physical Functioning: Demonstrates high internal consistency across cultures, with α coefficients consistently between 0.70 and 0.86.
• Role Functioning: In Version 1.0, role functioning employed a 2-point dichotomous response format which resulted in marginal reliability (α = 0.52 to 0.65). In Version 3.0, this was expanded to the 4-point response scale, elevating Cronbach’s α to between 0.78 and 0.88 across international samples.
• Emotional Functioning: Exhibits high internal consistency, with α values ranging between 0.73 and 0.90.
• Cognitive Functioning: Comprising two items (concentration and memory), this scale occasionally registers modest internal consistency (α ≈ 0.51 to 0.73), attributable to the statistical effect of a two-item operationalization and the partial divergence between attentional and mnemonic processes.
• Social Functioning: Generates reliable performance, with α coefficients ranging from 0.68 to 0.86.
• Fatigue: Shows high reliability across international cohorts, with α consistently falling between 0.77 and 0.89.
• Pain: Achieves internal consistency estimates between 0.76 and 0.89.
• Nausea and Vomiting: Displays α values ranging from 0.50 to 0.86; lower coefficients are occasionally observed in cohorts receiving modern antiemetic regimens with strong floor effects (absence of vomiting).
• Global Health Status / QoL: Demonstrates robust internal consistency across populations, with α consistently spanning 0.82 to 0.91.

Test-Retest Reliability

In stable patient cohorts re-assessed across brief intervals (ranging from 24 hours to 2 weeks where no intervening treatment changes occurred), the QLQ-C30 demonstrates excellent test-retest reproducibility. Intraclass correlation coefficients (ICCs) for functional scales range between 0.80 and 0.93, while symptom scales typically yield ICCs between 0.72 and 0.88. Minimal random measurement error indicates that the questionnaire is well suited for repeated-measures longitudinal clinical trials.

Factor Analysis

The structural dimensionality and latent organization of the EORTC QLQ-C30 have been verified via both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA), alongside multi-sample structural equation modeling evaluating cross-cultural measurement invariance.

Confirmatory Factor Structure

CFA investigations evaluating the hypothesized 15-domain measurement model demonstrate good goodness-of-fit indices across diverse populations. Standard structural modeling establishes that a multidimensional correlated-factor model or higher-order hierarchical structure satisfies modern fit criteria:

• Comparative Fit Index (CFI): Values consistently exceed 0.92 to 0.96.
• Tucker-Lewis Index (TLI): Typically spans 0.91 to 0.95.
• Root Mean Square Error of Approximation (RMSEA): Consistently maintains values ≤ 0.05 to 0.07, indicating an acceptable to close model fit.
• Standardized Root Mean Square Residual (SRMR): Frequently falls below 0.06.

Standardized factor loadings for items onto their targeted latent factors are strong: items 1–5 load onto Physical Functioning between 0.65 and 0.88; items 6–7 load onto Role Functioning between 0.75 and 0.92; items 21–24 load onto Emotional Functioning between 0.68 and 0.87; items 10, 12, and 18 load onto Fatigue between 0.72 and 0.89; and items 29–30 load onto Global Health Status with loadings typically exceeding 0.85.

Measurement Invariance and Modern Psychometrics

Large-scale cross-cultural psychometric analyses conducted across European, North American, Latin American, and Asian oncology trial participants confirm configural and metric measurement invariance across diverse cultural cohorts and between genders. Advanced Item Response Theory (IRT) and Rasch modeling analyses have demonstrated that most items operate with minimal Differential Item Functioning (DIF) across age groups, cultural settings, and disease stages. Some researchers have also evaluated higher-order summary scores, confirming that a two-factor second-order configuration (Physical Health Summary and Mental Health Summary) or an overarching QLQ-C30 Summary Score can be psychometrically justified when a single composite index is needed for clinical trials.

Instrument / Measurement Tool

• Instrument Type: Standardized, self-administered patient-reported outcome measure (PROM) / psychometric health-related quality of life survey.
• Target Population: Adult patients (aged 18 and older) diagnosed with any form or stage of malignant oncological disease.
• Administration Modality: Traditional paper-and-pencil completion, validated touchscreen computer tablets, electronic clinical outcome assessment (eCOA) platforms, interactive web portals, and structured telephone interviews.
• Time to Complete: Approximately 7 to 11 minutes for the majority of cancer patients.
• Item Configuration: Exactly 30 discrete survey items divided into functional dimensions, symptom dimensions, and global health status:
• Physical Functioning (PF): Items 1, 2, 3, 4, 5
• Role Functioning (RF): Items 6, 7
• Emotional Functioning (EF): Items 21, 22, 23, 24
• Cognitive Functioning (CF): Items 20, 25
• Social Functioning (SF): Items 26, 27
• Global Health Status / Quality of Life (QL): Items 29, 30
• Fatigue (FA): Items 10, 12, 18
• Nausea and Vomiting (NV): Items 14, 15
• Pain (PA): Items 9, 19
• Dyspnea (DY): Item 8
• Insomnia (SL): Item 11
• Appetite Loss (AP): Item 13
• Constipation (CO): Item 16
• Diarrhea (DI): Item 17
• Financial Difficulties (FI): Item 28
• Recall Period: Items 1–5 evaluate current physiological ability; Items 6–30 evaluate experiences during "the past week".
• Response Categories:
  • Items 1–28: 4-point Likert scale: 1 = "Not at All", 2 = "A Little", 3 = "Quite a Bit", 4 = "Very Much".
  • Items 29–30: 7-point modified linear analog scale: 1 = "Very poor" to 7 = "Excellent".
• Standardized Scoring Methodology (Fayers et al., 2001):
  • Step 1: Compute Raw Score (RS): Calculate the arithmetic mean of the items comprising the scale: $$RS = \frac{I_1 + I_2 + dots + I_k}{k}$$
  • Step 2: Linear Transformation to 0–100 Scale: Standardize the raw score onto a 0 to 100 continuum using the theoretical range ($Range = Max – Min$):
  • For Functional Scales: $$Score = \left[1 – \frac{RS – 1}{Range}\right] \times 100$$ (where Range = 3; a higher score represents superior functioning/health).
  • For Symptom Scales and Single Items: $$Score = \left[\frac{RS – 1}{Range}\right] \times 100$$ (where Range = 3; a higher score represents greater symptom burden/impairment).
  • For Global Health Status / QoL Scale: $$Score = \left[\frac{RS – 1}{Range}\right] \times 100$$ (where Range = 6, since items 29 and 30 range from 1 to 7; a higher score represents higher overall quality of life).

Permissions & Fee and Test Year

The EORTC Quality of Life Questionnaire was originally published in its prototype format (QLQ-C36) in 1987, followed by the definitive validation of the QLQ-C30 (Version 1.0) in 1993. The current standard version utilized globally is Version 3.0, finalized in 2001.

Licensing and Intellectual Property: The EORTC QLQ-C30 and its disease-specific modules are the intellectual property of the European Organisation for Research and Treatment of Cancer. Usage policies depend on the context:

• Academic and Non-Commercial Research: Use of the instrument is provided free of charge for non-commercial academic research, investigator-initiated academic clinical trials, graduate theses, and routine institutional clinical care. However, formal registration and approval via the official EORTC Quality of Life Department portal (https://qol.eortc.org/) is mandatory prior to administration.
• Commercial and Industry-Sponsored Research: Commercial entities, pharmaceutical corporations, contract research organizations (CROs), and for-profit entities conducting sponsored clinical drug trials must purchase a formal commercial license from the EORTC Quality of Life Group. User fees are structured based on study size, protocol complexity, and the number of translated language versions requested.

References

• Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., de Haes, J. C., Kaasa, S., Klee, M., Osoba, D., Razavi, D., Rofe, P. B., Schraub, S., Sneeuw, K., Sullivan, M., & Takeda, F. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376. https://doi.org/10.1093/jnci/85.5.365
• Cocks, K., King, M. T., Velikova, G., Martyn-St James, M., Fayers, P. M., & Brown, J. M. (2011). Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Journal of Clinical Oncology, 29(1), 89–96. https://doi.org/10.1200/JCO.2010.28.0107
• Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. Science, 196(4286), 129–136. https://doi.org/10.1126/science.847460
• Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001). The EORTC QLQ-C30 Scoring Manual (3rd ed.). European Organisation for Research and Treatment of Cancer. Brussels, Belgium.
• King, M. T. (1996). The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Quality of Life Research, 5(6), 555–567. https://doi.org/10.1007/BF00439229
• McDowell, I. (2006). Measuring Health: A Guide to Rating Scales and Questionnaires (3rd ed.). Oxford University Press. https://doi.org/10.1093/acprof:oso/9780195165678.001.0001
• Montazeri, A., Harirchi, I., Vahdani, M., Khaleghi, F., Jarvandi, S., Ebrahimi, M., & Haji-Mahmoodi, M. (1999). The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Translation and validation study of the Iranian version. Supportive Care in Cancer, 7(6), 400–406. https://doi.org/10.1007/s005200050300
• Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16(1), 139–144. https://doi.org/10.1200/JCO.1998.16.1.139
• Safaee, A., & Moghimi-Dehkordi, B. (2007). Validation study of a quality of life (QOL) questionnaire for use in Iran. Asian Pacific Journal of Cancer Prevention, 8(4), 543–546.
• Sprangers, M. A., Cull, A., Bjordal, K., Groenvold, M., & Aaronson, N. K. (1993). The European Organization for Research and Treatment of Cancer approach to quality of life assessment: Guidelines for developing questionnaire modules. Quality of Life Research, 2(4), 287–295. https://doi.org/10.1007/BF00434798
• Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA, 273(1), 59–65. https://doi.org/10.1001/jama.1995.03520250075037

13. Items of the Scale (Questionnaire)